<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Physiotherapy, Balneology and Rehabilitation</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Physiotherapy, Balneology and Rehabilitation</journal-title><trans-title-group xml:lang="ru"><trans-title>Физиотерапия, бальнеология и реабилитация</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1681-3456</issn><issn publication-format="electronic">2413-2969</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">109603</article-id><article-id pub-id-type="doi">10.17816/rjpbr109603</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Review</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Low-level laser therapy in the supportive treatment of dermatologic adverse events in oncology</article-title><trans-title-group xml:lang="ru"><trans-title>Низкоинтенсивная лазерная терапия в сопроводительном лечении дерматологических нежелательных явлений в онкологии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6888-4760</contrib-id><contrib-id contrib-id-type="spin">8039-4105</contrib-id><name-alternatives><name xml:lang="en"><surname>Polonskaia</surname><given-names>Aleksandra S.</given-names></name><name xml:lang="ru"><surname>Полонская</surname><given-names>Александра Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Postgraduate Student</p></bio><bio xml:lang="ru"><p>аспирант</p></bio><email>dr.polonskaia@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0238-6563</contrib-id><contrib-id contrib-id-type="spin">3827-0100</contrib-id><name-alternatives><name xml:lang="en"><surname>Shatokhina</surname><given-names>Evgeniya  A.</given-names></name><name xml:lang="ru"><surname>Шатохина</surname><given-names>Евгения Афанасьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>e.a.shatokhina@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5044-5265</contrib-id><contrib-id contrib-id-type="spin">1107-4372</contrib-id><name-alternatives><name xml:lang="en"><surname>Kruglova</surname><given-names>Larisa S.</given-names></name><name xml:lang="ru"><surname>Круглова</surname><given-names>Лариса Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>kruglovals@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Central State Medical Academy of Department of Presidential affairs</institution></aff><aff><institution xml:lang="ru">Центральная государственная медицинская академия Управления делами Президента Российской Федерации</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Medical Scientific and Educational Center of Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">Медицинский научно-образовательный центр Московского государственного университета имени М.В. Ломоносова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-12-03" publication-format="electronic"><day>03</day><month>12</month><year>2022</year></pub-date><volume>21</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>131</fpage><lpage>141</lpage><history><date date-type="received" iso-8601-date="2022-08-03"><day>03</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-10-24"><day>24</day><month>10</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Polonskaia A.S., Shatokhina E.A., Kruglova L.S.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Полонская А.С., Шатохина Е.А., Круглова Л.С.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Polonskaia A.S., Shatokhina E.A., Kruglova L.S.</copyright-holder><copyright-holder xml:lang="ru">Полонская А.С., Шатохина Е.А., Круглова Л.С.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://rjpbr.com/1681-3456/article/view/109603">https://rjpbr.com/1681-3456/article/view/109603</self-uri><abstract xml:lang="en"><p>Supportive treatment plays an important role in oncology nowadays. The main aims of oncologic supportive treatment are management of cancer symptoms and adverse events of cancer treatment.</p> <p>In terms of dermatologic adverse events the most important types of reaction are oral mucositis during radiation therapy, chemotherapy and during hematopoetic stem cell transplantation, palmoplantar syndrome during chemotherapy, palmoplantar skin reaction, acneiform paronychia and pyogenic granulomas during targeted therapy, immune-related dermatologic adverse events during immunotherapy.</p> <p>During recent years, special attention has been paid to low level laser therapy for the prophylaxis and management of cancer therapy dermatologic adverse events. The effects of low level laser therapy may have a beneficial effect on many conditions that play important roles in the pathogenesis of radiation and chemotherapy-induced complications in oncologic patients. Therapeutic effects of low level laser therapy are attributed to the stimulation of adaptive processes and to the increase of nonspecific resistance. The latter develop due to the close interaction of the immune, humoral and nervous systems. When choosing a method for the supportive treatment of cancer therapy adverse events, it is extremely important to establish safety in terms of the tumor process and absence of negative effects on cancer treatment.</p> <p>Effects of low level laser therapy on the proliferative and invasive activity of an existing malignancy remains a matter of debate due to conflicting results from in vitro studies.</p> <p>At the same time, according to the results of numerous clinical studies, the use of this method is assumed to be safe for cancer patients.</p></abstract><trans-abstract xml:lang="ru"><p>В настоящее время сопроводительная терапия занимает важное место в онкологии. Основными задачами сопроводительного лечения онкологических пациентов является купирование симптомов злокачественных новообразований и нежелательных явлений проводимого противоопухолевого лечения.</p> <p>В отношении дерматологических нежелательных явлений наиболее значимыми являются оральные мукозиты на фоне лучевой терапии, химиотерапии и при трансплантации гемопоэтических стволовых клеток; ладонно-подошвенный синдром при проведении химиотерапии; ладонно-подошвенная кожная реакция, акнеподобная сыпь, паронихии и пиогенные гранулёмы при проведении таргетной противоопухолевой терапии; иммуноопосредованные дерматологические нежелательные явления на фоне иммунотерапии.</p> <p>В последние годы особое внимание уделяется низкоинтенсивной лазерной терапии как методу профилактики и лечения дерматологических нежелательных явлений противоопухолевой терапии. Эффекты низкоинтенсивной лазерной терапии могут оказывать благоприятное влияние на многие процессы, играющие роль в развитии дерматологических осложнений у онкологических больных. Лечебный эффект низкоинтенсивной лазерной терапии обеспечивается стимуляцией адаптивных процессов организма и повышением неспецифической резистентности, что обусловлено тесным взаимодействием нервной, гуморальной и иммунной систем.</p> <p>При выборе метода сопроводительного лечения нежелательных явлений противоопухолевой терапии крайне важно установить безопасность в отношении опухолевого процесса и отсутствие отрицательного влияния на эффективность проводимого противоопухолевого лечения.</p> <p>Влияние низкоинтенсивной лазерной терапии на пролиферативную и инвазивную активность существующего злокачественного новообразования остаётся предметом дискуссии ввиду противоречивых результатов исследований in vitro, однако, по результатам клинических исследований, использование данного метода представляется безопасным для онкологических пациентов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>low-level laser therapy</kwd><kwd>dermatologic adverse events</kwd><kwd>cancer therapy</kwd><kwd>rehabilitation</kwd><kwd>supportive treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>низкоинтенсивная лазерная терапия</kwd><kwd>дерматологические нежелательные явления</kwd><kwd>противоопухолевая терапия</kwd><kwd>восстановительное лечение</kwd><kwd>поддерживающая терапия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">US Department of Health and Human Services et al. Common terminology criteria for adverse events (CTCAE) version 4.0 (May 28, 2009). National Institute of Health, National Cancer Institute v.4.03: June 14, 2010. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed: 15.12.2021.</mixed-citation><mixed-citation xml:lang="ru">US Department of Health and Human Services et al. Common terminology criteria for adverse events (CTCAE) version 4.0 (May 28, 2009). National Institute of Health, National Cancer Institute v.4.03: June 14, 2010. Режим доступа: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Дата обращения: 15.12.2021.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Rosen AC, Case EC, Dusza SW, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–333. doi: 10.1007/s40257-013-0021-0</mixed-citation><mixed-citation xml:lang="ru">Rosen A.C., Case E.C., Dusza S.W., et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic // Am J Clin Dermatol. 2013. Vol. 14, N 4. Р. 327–333. doi: 10.1007/s40257-013-0021-0</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079–1095. doi: 10.1007/s00520-011-1197-6</mixed-citation><mixed-citation xml:lang="ru">Lacouture M.E., Anadkat M.J., Bensadoun R.J., et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities // Support Care Cancer. 2011. Vol. 19, N 8. Р. 1079–1095. doi: 10.1007/s00520-011-1197-6</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Lacouture ME, Sibaud V, Gerber PA, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(2):157–170. doi: 10.1016/j.annonc.2020.11.005</mixed-citation><mixed-citation xml:lang="ru">Lacouture M.E., Sibaud V., Gerber P.A., et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines // Ann Oncol. 2021. Vol. 32, N 2. Р. 157–170. doi: 10.1016/j.annonc.2020.11.005</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Koroleva IA, Bolotina LV, Gladkov OA, et al. Practical recommendations on the management of dermatologic adverse events in patients, treated with targeted anticancer. Prakticheskie rekomendatsii RUSSCO #3s2. 2020;10(42):88–101. (In Russ). doi: 10.18027/2224-5057-2020-10-3s2-42</mixed-citation><mixed-citation xml:lang="ru">Королева И. А., Болотина Л. В., Гладков О. А., и др. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию // Практические рекомендации RUSSCO #3s2. 2020. Т. 10, № 42. C. 88–101. doi: 10.18027/2224-5057-2020-10-3s2-42</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Elad S, Cheng KK, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126(19):4423–4431. doi: 10.1002/cncr.33100</mixed-citation><mixed-citation xml:lang="ru">Elad S., Cheng K.K., Lalla R.V., et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy // Cancer. 2020. Vol. 126, N 19. Р. 4423–4431. doi: 10.1002/cncr.33100</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Potekaev NN, Kruglova LS. Laser in dermatology and cosmetology. Moscow: MDV; 2012. 280 р. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Потекаев Н.Н., Круглова Л.С. Лазер в дерматологии и косметологии. Москва: МДВ, 2012. 280 с.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">General physiotherapy: textbook. Electronic edition. Ed. by G.N. Ponomarenko. 5th ed., revised and updated. Moscow: GEOTAR-Media; 2014. 368 p. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Общая физиотерапия: учебник. Электронное издание / под ред. Г.Н. Пономаренко. 5-е изд., перераб. и доп. Москва: ГЭОТАР-Медиа, 2014. 368 с.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Zecha JA, Raber-Durlacher JE, Nair RG, et al. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Support Care Cancer. 2016;24(6):2781–2792. doi: 10.1007/s00520-016-3152-z</mixed-citation><mixed-citation xml:lang="ru">Zecha J.A., Raber-Durlacher J.E., Nair R.G., et al. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations // Support Care Cancer. 2016. Vol. 24, N 6. Р. 2781–2792. doi: 10.1007/s00520-016-3152-z</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Bjordal JM, Johnson MI, Iversen V, et al. Low-level laser therapy in acute pain: a systematic review of possible mechanisms of action and clinical effects in randomized placebo-controlled trials. Photomed Laser Surg. 2006;24(2):158–168. doi: 10.1089/pho.2006.24.158</mixed-citation><mixed-citation xml:lang="ru">Bjordal J.M., Johnson M.I., Iversen V., et al. Low-level laser therapy in acute pain: a systematic review of possible mechanisms of action and clinical effects in randomized placebo-controlled trials // Photomed Laser Surg. 2006. Vol. 24, N 2. Р. 158–168. doi: 10.1089/pho.2006.24.158</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors — a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10(5):470–481. doi: 10.2174/138920009788897975</mixed-citation><mixed-citation xml:lang="ru">Hartmann J.T., Haap M., Kopp H.G., Lipp H.P. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects // Curr Drug Metab. 2009. Vol. 10, N 5. Р. 470–481. doi: 10.2174/138920009788897975</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Huang YY, Sharma SK, Carroll J, Hamblin MR. Biphasic dose response in low level light therapy - an update. Dose Response. 2011;9(4):602–618. doi: 10.2203/dose-response.11-009.Hamblin</mixed-citation><mixed-citation xml:lang="ru">Huang Y.Y., Sharma S.K., Carroll J., Hamblin M.R. Biphasic dose response in low level light therapy — an update // Dose Response. 2011. Vol. 9, N 4. Р. 602–618. doi: 10.2203/dose-response.11-009.Hamblin</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Hawkins D, Abrahamse H. Biological effects of helium-neon laser irradiation on normal and wounded human skin fibroblasts. Photomed Laser Surg. 2005;23(3):251–259. doi: 10.1089/pho.2005.23.251</mixed-citation><mixed-citation xml:lang="ru">Hawkins D., Abrahamse H. Biological effects of helium-neon laser irradiation on normal and wounded human skin fibroblasts // Photomed Laser Surg. 2005. Vol. 23, N 3. Р. 251–259. doi: 10.1089/pho.2005.23.251</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Schartinger VH, Galvan O, Riechelmann H, Dudás J. Differential responses of fibroblasts, non-neoplastic epithelial cells, and oral carcinoma cells to low-level laser therapy. Support Care Cancer. 2012;20(3):523–529. doi: 10.1007/s00520-011-1113-0</mixed-citation><mixed-citation xml:lang="ru">Schartinger V.H., Galvan O., Riechelmann H., Dudás J. Differential responses of fibroblasts, non-neoplastic epithelial cells, and oral carcinoma cells to low-level laser therapy // Support Care Cancer. 2012. Vol. 20, N 3. Р. 523–529. doi: 10.1007/s00520-011-1113-0</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Powell K, Low P, McDonnell PA, et al. The effect of laser irradiation on proliferation of human breast carcinoma, melanoma, and immortalized mammary epithelial cells. Photomed Laser Surg. 2010;28(1):115–123. doi: 10.1089/pho.2008.2445</mixed-citation><mixed-citation xml:lang="ru">Powell K., Low P., McDonnell P.A., et al. The effect of laser irradiation on proliferation of human breast carcinoma, melanoma, and immortalized mammary epithelial cells // Photomed Laser Surg. 2010. Vol. 28, N 1. Р. 115–123. doi: 10.1089/pho.2008.2445</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Henriques ÁC, Ginani F, Oliveira RM, et al. Low-level laser therapy promotes proliferation and invasion of oral squamous cell carcinoma cells. Lasers Med Sci. 2014;29(4):1385–1395. doi: 10.1007/s10103-014-1535-2</mixed-citation><mixed-citation xml:lang="ru">Henriques Á.C., Ginani F., Oliveira R.M., et al. Low-level laser therapy promotes proliferation and invasion of oral squamous cell carcinoma cells // Lasers Med Sci. 2014. Vol. 29, N 4. Р. 1385–1395. doi: 10.1007/s10103-014-1535-2</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Pellicioli AC, Martins MD, Dillenburg CS, et al. Laser phototherapy accelerates oral keratinocyte migration through the modulation of the mammalian target of rapamycin signaling pathway. J Biomed Opt. 2014;19(2):028002. doi: 10.1117/1.JBO.19.2.028002</mixed-citation><mixed-citation xml:lang="ru">Pellicioli A.C., Martins M.D., Dillenburg C.S., et al. Laser phototherapy accelerates oral keratinocyte migration through the modulation of the mammalian target of rapamycin signaling pathway // J Biomed Opt. 2014. Vol. 19, N 2. Р. 028002. doi: 10.1117/1.JBO.19.2.028002</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Simpson DR, Mell LK, Cohen EE. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2015;51(4):291–298. doi: 10.1016/j.oraloncology.2014.11.012</mixed-citation><mixed-citation xml:lang="ru">Simpson D.R., Mell L.K., Cohen E.E. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck // Oral Oncol. 2015. Vol. 51, N 4. Р. 291–298. doi: 10.1016/j.oraloncology.2014.11.012</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Nagata Y, Takahashi A, Ohnishi K, et al. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. Int J Oncol. 2010;37(4):1001–1010. doi: 10.3892/ijo_00000751</mixed-citation><mixed-citation xml:lang="ru">Nagata Y., Takahashi A., Ohnishi K., et al. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status // Int J Oncol. 2010. Vol. 37, N 4. Р. 1001–1010. doi: 10.3892/ijo_00000751</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Chang L, Graham PH, Hao J, et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 2013;4(10):e875. doi: 10.1038/cddis.2013.407</mixed-citation><mixed-citation xml:lang="ru">Chang L., Graham P.H., Hao J., et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance // Cell Death Dis. 2013. Vol. 4, N 10. Р. e875. doi: 10.1038/cddis.2013.407</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Sperandio FF, Giudice FS, Corrêa L, et al. Low-level laser therapy can produce increased aggressiveness of dysplastic and oral cancer cell lines by modulation of Akt/mTOR signaling pathway. J Biophotonics. 2013;6(10):839–847. doi: 10.1002/jbio.201300015</mixed-citation><mixed-citation xml:lang="ru">Sperandio F.F., Giudice F.S., Corrêa L., et al. Low-level laser therapy can produce increased aggressiveness of dysplastic and oral cancer cell lines by modulation of Akt/mTOR signaling pathway // J Biophotonics. 2013. Vol. 6, N 10. Р. 839–847. doi: 10.1002/jbio.201300015</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–3290. doi: 10.1038/sj.onc.1210421</mixed-citation><mixed-citation xml:lang="ru">Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer // Oncogene. 2007. Vol. 26, N 22. Р. 3279–3290. doi: 10.1038/sj.onc.1210421</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Guo YJ, Pan WW, Liu SB, et al. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19(3):1997–2007. doi: 10.3892/etm.2020.8454</mixed-citation><mixed-citation xml:lang="ru">Guo Y.J., Pan W.W., Liu S.B., et al. ERK/MAPK signalling pathway and tumorigenesis // Exp Ther Med. 2020. Vol. 19, N 3. Р. 1997–2007. doi: 10.3892/etm.2020.8454</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Cui X, Li S, Li T, et al. Significance of elevated ERK expression and its positive correlation with EGFR in Kazakh patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014;7(5):2382–2391.</mixed-citation><mixed-citation xml:lang="ru">Cui X., Li S., Li T., et al. Significance of elevated ERK expression and its positive correlation with EGFR in Kazakh patients with esophageal squamous cell carcinoma // Int J Clin Exp Pathol. 2014. Vol. 7, N 5. Р. 2382–2391.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta. 2007;1775(1):21–62. doi: 10.1016/j.bbcan.2006.06.004</mixed-citation><mixed-citation xml:lang="ru">Pardali K., Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer // Biochim Biophys Acta. 2007. Vol. 1775, N 1. Р. 21–62. doi: 10.1016/j.bbcan.2006.06.004</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Principe DR, Doll JA, Bauer J, et al. TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 2014;106(2):djt369. doi: 10.1093/jnci/djt369</mixed-citation><mixed-citation xml:lang="ru">Principe D.R., Doll J.A., Bauer J., et al. TGF-β: duality of function between tumor prevention and carcinogenesis // J Natl Cancer Inst. 2014. Vol. 106, N 2. Р. djt369. doi: 10.1093/jnci/djt369</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Siegel PM, Massagué J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003;3(11):807–821. doi: 10.1038/nrc1208</mixed-citation><mixed-citation xml:lang="ru">Siegel P.M., Massagué J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer // Nat Rev Cancer. 2003. Vol. 3, N 11. Р. 807–821. doi: 10.1038/nrc1208</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Hwang YS, Park KK, Chung WY. Stromal transforming growth factor-beta 1 is crucial for reinforcing the invasive potential of low invasive cancer. Arch Oral Biol. 2014;59(7):687–694. doi: 10.1016/j.archoralbio.2014.03.017</mixed-citation><mixed-citation xml:lang="ru">Hwang Y.S., Park K.K., Chung W.Y. Stromal transforming growth factor-beta 1 is crucial for reinforcing the invasive potential of low invasive cancer // Arch Oral Biol. 2014. Vol. 59, N 7. Р. 687–694. doi: 10.1016/j.archoralbio.2014.03.017</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Prime SS, Davies M, Pring M, Paterson IC. The role of TGF-beta in epithelial malignancy and its relevance to the pathogenesis of oral cancer (part II). Crit Rev Oral Biol Med. 2004;15(6):337–347. doi: 10.1177/154411130401500603</mixed-citation><mixed-citation xml:lang="ru">Prime S.S., Davies M., Pring M., Paterson I.C. The role of TGF-beta in epithelial malignancy and its relevance to the pathogenesis of oral cancer (part II) // Crit Rev Oral Biol Med. 2004. Vol. 15, N 6. Р. 337–347. doi: 10.1177/154411130401500603</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Medical rehabilitation. Book 1. Ed. by V.M. Bogolyubov. Moscow: BINOM; 2010. 416 p. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Медицинская реабилитация. Книга 1 / под ред. В.М. Боголюбова. Москва: БИНОМ, 2010. 416 с.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Becker A, van Wijk A, Smit EF, Postmus PE. Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. J Thorac Oncol. 2010;5(9):1477–1480. doi: 10.1097/JTO.0b013e3181e981d9</mixed-citation><mixed-citation xml:lang="ru">Becker A., van Wijk A., Smit E.F., Postmus P.E. Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer // J Thorac Oncol. 2010. Vol. 5, N 9. Р. 1477–1480. doi: 10.1097/JTO.0b013e3181e981d9</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Schaffer M, Sroka R, Fuchs C, et al. Biomodulative effects induced by 805 nm laser light irradiation of normal and tumor cells. J Photochem Photobiol B. 1997;40(3):253–257. doi: 10.1016/s1011-1344(97)00065-1</mixed-citation><mixed-citation xml:lang="ru">Schaffer M., Sroka R., Fuchs C., et al. Biomodulative effects induced by 805 nm laser light irradiation of normal and tumor cells // J Photochem Photobiol B. 1997. Vol. 40, N 3. Р. 253–257. doi: 10.1016/s1011-1344(97)00065-1</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Sroka R, Schaffer M, Fuchs C, et al. Effects on the mitosis of normal and tumor cells induced by light treatment of different wavelengths. Lasers Surg Med. 1999;25(3):263–271. doi: 10.1002/(sici)1096-9101(1999)25:3&lt;263::aid-lsm11&gt;3.0.co;2-t</mixed-citation><mixed-citation xml:lang="ru">Sroka R., Schaffer M., Fuchs C., et al. Effects on the mitosis of normal and tumor cells induced by light treatment of different wavelengths // Lasers Surg Med. 1999. Vol. 25, N 3. Р. 263–271. doi: 10.1002/(sici)1096-9101(1999)25:3&lt;263::aid-lsm11&gt;3.0.co;2-t</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Kreisler M, Christoffers AB, Willershausen B, d'Hoedt B. Low-level 809 nm GaAlAs laser irradiation increases the proliferation rate of human laryngeal carcinoma cells in vitro. Lasers Med Sci. 2003;18(2):100–103. doi: 10.1007/s10103-003-0265-7</mixed-citation><mixed-citation xml:lang="ru">Kreisler M., Christoffers A.B., Willershausen B., d'Hoedt B. Low-level 809 nm GaAlAs laser irradiation increases the proliferation rate of human laryngeal carcinoma cells in vitro // Lasers Med Sci. 2003. Vol. 18, N 2. Р. 100–103. doi: 10.1007/s10103-003-0265-7</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">Liu YH, Cheng CC, Ho CC, et al. Effects of diode 808 nm GaAlAs low-power laser irradiation on inhibition of the proliferation of human hepatoma cells in vitro and their possible mechanism. Res Commun MolPathol Pharmacol. 2004;115-116:185–201.</mixed-citation><mixed-citation xml:lang="ru">Liu Y.H., Cheng C.C., Ho C.C., et al. Effects of diode 808 nm GaAlAs low-power laser irradiation on inhibition of the proliferation of human hepatoma cells in vitro and their possible mechanism // Res Commun Mol Pathol Pharmacol. 2004. Vol. 115-116. Р. 185–201.</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">Werneck CE, Pinheiro AL, Pacheco MT, et al. Laser light is capable of inducing proliferation of carcinoma cells in culture: a spectroscopic in vitro study. Photomed Laser Surg. 2005;23(3):300–303. doi: 10.1089/pho.2005.23.300</mixed-citation><mixed-citation xml:lang="ru">Werneck C.E., Pinheiro A.L., Pacheco M.T., et al. Laser light is capable of inducing proliferation of carcinoma cells in culture: a spectroscopic in vitro study // Photomed Laser Surg. 2005. Vol. 23, N 3. Р. 300–303. doi: 10.1089/pho.2005.23.300</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Al-Watban FA, Andres BL. Laser biomodulation of normal and neoplastic cells. Lasers Med Sci. 2012;27(5):1039–1043. doi: 10.1007/s10103-011-1040-9</mixed-citation><mixed-citation xml:lang="ru">Al-Watban F.A., Andres B.L. Laser biomodulation of normal and neoplastic cells // Lasers Med Sci. 2012. Vol. 27, N 5. Р. 1039–1043. doi: 10.1007/s10103-011-1040-9</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">Murayama H, Sadakane K, Yamanoha B, Kogure S. Low-power 808-nm laser irradiation inhibits cell proliferation of a human-derived glioblastoma cell line in vitro. Lasers Med Sci. 2012;27(1):87–93. doi: 10.1007/s10103-011-0924-z</mixed-citation><mixed-citation xml:lang="ru">Murayama H., Sadakane K., Yamanoha B., Kogure S. Low-power 808-nm laser irradiation inhibits cell proliferation of a human-derived glioblastoma cell line in vitro // Lasers Med Sci. 2012. Vol. 27, N 1. Р. 87–93. doi: 10.1007/s10103-011-0924-z</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">Antunes HS, Herchenhorn D, Small IA, et al. Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis. Oral Oncol. 2017;71:11–15. doi: 10.1016/j.oraloncology.2017.05.018</mixed-citation><mixed-citation xml:lang="ru">Antunes H.S., Herchenhorn D., Small I.A., et al. Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis // Oral Oncol. 2017. Vol. 71. Р. 11–15. doi: 10.1016/j.oraloncology.2017.05.018</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">Brandão TB, Morais-Faria K, Ribeiro AC, et al. Locally advanced oral squamous cell carcinoma patients treated with photobiomodulation for prevention of oral mucositis: retrospective outcomes and safety analyses. Support Care Cancer. 2018;26(7):2417–2423. doi: 10.1007/s00520-018-4046-z</mixed-citation><mixed-citation xml:lang="ru">Brandão T.B., Morais-Faria K., Ribeiro A.C., et al. Locally advanced oral squamous cell carcinoma patients treated with photobiomodulation for prevention of oral mucositis: retrospective outcomes and safety analyses // Support Care Cancer. 2018. Vol. 26, N 7. Р. 2417–2423. doi: 10.1007/s00520-018-4046-z</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">Bensadoun RJ, Epstein JB, Nair RG, et al. Safety and efficacy of photobiomodulation therapy in oncology: a systematic review. Cancer Med. 2020;9(22):8279–8300. doi: 10.1002/cam4.3582</mixed-citation><mixed-citation xml:lang="ru">Bensadoun R.J., Epstein J.B., Nair R.G., et al. Safety and efficacy of photobiomodulation therapy in oncology: A systematic review // Cancer Med. 2020. Vol. 9, N 22. Р. 8279–8300. doi: 10.1002/cam4.3582</mixed-citation></citation-alternatives></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">Genot-Klastersky MT, Paesmans M, Ameye L, et al. Retrospective evaluation of the safety of low-level laser therapy/photobiomodulation in patients with head/neck cancer. Support Care Cancer. 2020;28(7):3015–3022. doi: 10.1007/s00520-019-05041-3</mixed-citation><mixed-citation xml:lang="ru">Genot-Klastersky M.T., Paesmans M., Ameye L., et al. Retrospective evaluation of the safety of low-level laser therapy/photobiomodulation in patients with head/neck cancer // Support Care Cancer. 2020. Vol. 28, N 7. Р. 3015–3022. doi: 10.1007/s00520-019-05041-3</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">Shatokhina EA, Kruglova LS, Korchazhkina NB. Modern views on adjuvant therapy of cancer patients against the background of targeted treatment. Fizioterapevt. 2016;(2):9–33. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Шатохина Е.А., Круглова Л.С., Корчажкина Н.Б. Современные взгляды на адъювантную терапию онкологических больных на фоне таргетного лечения // Физиотерапевт. 2016. № 2. С. 9–33.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
